AndreiHoriaIagaruMD

Nuclear Medicine • Stanford, CA

Professor, Radiology, Stanford University Medical Center

Join to view full profile

Dr. Iagaru is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Iagaru's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5047

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Nuclear Medicine, 2004 - 2006
Graduate HospitalInternship, Internal Medicine, 2003 - 2004
Carol Davila University of Medicine and PharmacyClass of 2000

Certifications & Licensure

CA State Medical License 2005 - 2025
PA State Medical License 2003 - 2004
American Board of Nuclear Medicine Nuclear Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA Start of enrollment: 2007 May 01
Withdrawn
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases Start of enrollment: 2006 Jan 01
Completed
Phase 2
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy Start of enrollment: 2007 Aug 01
Completed
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
No longer available
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Start of enrollment: 2014 Dec 01
Terminated
Not Applicable
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment Start of enrollment: 2017 May 20
Completed
Phase 2, Phase 3
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery Start of enrollment: 2016 Apr 18
Completed
Phase 2, Phase 3
Standard PET/CT vs. Digital PET/CT Start of enrollment: 2017 Mar 29
Completed
Not Applicable
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Start of enrollment: 2017 Aug 02
Terminated
Phase 2
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors Start of enrollment: 2017 Feb 15
Completed
Not Applicable
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer Start of enrollment: 2017 Apr 10
Completed
Phase 2
PET/MRI Evaluation of Cardiac Amyloid Start of enrollment: 2016 May 26
Completed
Early Phase 1
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals Start of enrollment: 2014 May 27
Completed
Phase 2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
No longer available
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer Start of enrollment: 2020 Dec 15
Completed
Phase 2
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer Start of enrollment: 2019 Jan 14
Completed
Phase 2
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy Start of enrollment: 2019 Apr 09
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Deep learning-based time-of-flight (ToF) enhancement of non-ToF PET scans for different radiotracers.
Abolfazl Mehranian, Scott D Wollenweber, Kevin M Bradley, Patrick A Fielding, Martin Huellner
European Journal of Nuclear Medicine and Molecular Imaging. 2025-02-18
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.
Riccardo Laudicella, Matteo Bauckneht, Irene A Burger, Alberto Cacciola, Stefano Fanti
European Journal of Nuclear Medicine and Molecular Imaging. 2025-02-12
Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine.
Clément Morgat, Andrei Iagaru, Elif Hindié
Journal of Nuclear Medicine. 2025-02-03

Journal Articles

Visualization of Diagnostic and Therapeutic Targets in Glioma with Molecular Imaging
Chirag B Patel, Guofan Xu, Andrei Iagaru, Frontiers in Immunology
18F-FPPRGD2 PET/CT in Patients with Metastatic Renal Cell Cancer
Alice C Fan, Andrei Iagaru, European Journal of Nuclear Medicine and Molecular Imaging

Press Mentions

JNM Podcast Episode 5: Healthcare Systems Readiness: What Is Limiting the RLT Scale-Up?August 28th, 2024
US Is Facing a ‘Historical’ Shortage of Life-Saving Cancer DrugsApril 11th, 2023
Imaging Technique Predicts Risk of Prostate Cancer Recurrence After TreatmentJanuary 11th, 2023
Join now to see all

External Links

Nuclear Medicinehttp://nuclearmedicine.stanford.edu/

AndreiHoriaIagaruMD

Dr. Iagaru is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

External Links

Viewing the full profile is available to verified healthcare professionals only.